Analyst Forecasts Near-Triple-Digit Upside for Viking Therapeutics Stock

A prominent analyst at investment bank H.C. Wainwright has reiterated a bullish stance on Viking Therapeutics, setting a price target that suggests massive potential gains for the biotech firm’s shares. The optimism stems not from new internal data, but rather from positive clinical developments reported by a major industry competitor, Eli Lilly.

Joseph Pantginis, an analyst at H.C. Wainwright, recently reaffirmed his “Buy” rating for Viking Therapeutics. He maintained a price objective of $102 per share. With the stock closing at $35.19 this past Friday, this target implies an upside of approximately 190 percent.

The catalyst for this renewed confidence emerged from Eli Lilly’s latest long-term data Read more...